Cancer Researchers Receive Grant to Study Indolent Neuroblastoma
|
PHILADELPHIA, April 20, 2021 /PRNewswire/ -- A trans-Atlantic collaborative group of researchers led by Children's Hospital of Philadelphia (CHOP) has received approximately $680,000 from a group of research charities led by Solving Kids' Cancer UK to study slowly progressive, or "indolent," neuroblastoma, which does not respond to chemotherapy and lacks other treatment options. The grant will fund research that could ultimately lead to better diagnosis of this form of the disease, as well as targeted treatment options. The interdisciplinary group involves researchers from CHOP; the Icahn School of Medicine at Mount Sinai; The Institute of Cancer Research, London; Texas Tech University Health Sciences Center; and Seattle Children's. "This grant will allow us to make progress in diagnosing and treating so-called indolent neuroblastoma, which is currently fatal in most patients," said principal investigator John M. Maris, MD, pediatric oncologist at the Cancer Center at CHOP and Giulio D'Angio Chair in Neuroblastoma Research at CHOP. "If we can identify signatures that allow us to diagnose this form of neuroblastoma in patients early, we can avoid unnecessary chemotherapy, which is not effective in these patients, and instead work toward targeted treatments that could ultimately improve patient outcomes." Neuroblastoma is a type of cancer that forms in developing nerve cells and can present differently depending on the form of the disease. Some types can spontaneously regress and become benign, whereas others progress steadily and are fatal. The rate of progression varies. While certain forms of the disease progress rapidly but can be treated effectively with chemotherapy, other forms, like indolent neuroblastoma, progress slowly and are resistant to chemotherapy. The latter form predominately affects older children, teenagers and adults, who have very little chance of surviving their disease. Currently, researchers lack tools to identify patients with indolent neuroblastoma and therapies with which to cure them. The joint award from Zoé4Life, Joining Against Cancer in Kids (JACK), Merryn Lacy Trust, Oscar Knox Fund, Solving Kids' Cancer (US) and Solving Kids' Cancer UK will allow the trans-Atlantic group of researchers to validate a specific and sensitive molecular test in tumors, which will be further developed for use with patient blood, in order to reliably identify patients with slowly progressing disease, rather than waiting for chemotherapy to fail them. The research team will also create and validate robust laboratory models of indolent neuroblastoma, which they will use to test combinations of immunotherapy with targeted small molecular therapies. Ultimately, the researchers hope to rapidly move a completely new therapy to an international clinical trial. "Putting your child through multiple rounds of chemotherapy and watching them suffer from horrible side-effects only to find it's made no difference to their disease is a truly devastating blow for parents," said Nick Bird, Research Trustee at Solving Kids' Cancer UK. "We have to identify these children at diagnosis so we can spare them from chemotherapy that doesn't work, and then we have to find better ways to treat their disease instead." About Children's Hospital of Philadelphia: Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. In addition, its unique family-centered care and public service programs have brought the 595-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu Contact: Jennifer Lee
SOURCE Children's Hospital of Philadelphia |
View original content: